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The prognostic value of multiparameter flow
cytometry minimal residual disease assessment in
relapsed multiple myeloma
Achieving deep levels of remission is one of the prereq-
uisites to reach long-term survival in solid tumors and
hematologic malignancies, and this has also been proved in
newly diagnosed multiple myeloma (MM) patients, partic-
ularly in the era of novel agents.1-3 Accordingly, both the
Spanish and UK groups have shown the prognostic value
and clinical relevance of minimal residual disease (MRD)
monitoring by multiparameter flow cytometry (MFC) in
both newly diagnosed transplant candidates and elderly
MM patients treated with novel agents.4-6 However, the
value of the depth of response in the relapse setting has
been subject to far less investigation than in the up-front
setting.7-11 In fact, there are few data exploring different out-
comes between patients achieving very good partial
response (VGPR) or complete response (CR) with salvage
therapy,7-11 and there is no information regarding the prog-
nostic value of achieving immunophenotypic or molecular
responses at relapse. If MRD-negativity translated into
superior outcomes, like those observed in newly diagnosed
patients, then it could become a desirable end point for
clinical trials exploring new drugs for relapse/refractory
patients.
In the present study, we focused on a total of 52 patients
who after clinical relapse achieved CR with salvage thera-
py. Patients were divided into two categories: 21 rescued
with novel agents followed by allogeneic stem cell trans-
plantation (alloSCT; n=21), and 31 patients rescued and
achieving CR with novel agents (in all except 6) followed or
not by autologous stem cell transplantation (autoSCT) (11
and 14 cases, respectively). 
All samples were collected after informed patient con-
sent according to the local ethical committees and the
Declaration of Helsinki protocol. Median follow up was 2.7
years (32 months). MFC studies were performed on bone
marrow (BM) samples using 4-color monoclonal antibody
combinations (FITC/PE/PerCPCy5.5/APC), as described
elsewhere.4,5,12 Plasma cells (PCs) were initially identified on
the basis of strong CD38 expression and intermediate side
scatter signals; discrimination between clonal and normal
PCs was performed by the recognition of aberrant pheno-
typic expression profiles such as simultaneous downregula-
tion of CD19 and CD45, with or without overexpression of
CD56. For patients in whom CD45 or CD19 was positively
expressed, lack of CD19 or CD45, respectively, dim CD38
intensity and/or bright CD56 staining (equal or higher than
that of natural killer cells) allowed identification of clonal
PCs in the vast majority of cases; in selected patients (n=7),
CD56 was replaced by CD28, CD81 or CD117 since these
markers were known to be more informative according to
the base-line phenotypic evaluation. Data acquisition was
performed in FACSCalibur and FACSCantoII flow cytome-
ters (Becton Dickinson Biosciences, BDB, San Jose, CA,
USA) using the FACSDiva 6.1 software (BDB), and a 2-step
acquisition procedure allowing for a minimum of 2x105
leukocytes/tube to be selectively stored. Data analysis was
performed using the Paint-a-Gate (BDB) and the Infinicyt
software (Cytognos SL, Salamanca, Spain). Patients were
defined as being MRD-negative when less than 20 clonal
PCs were detectable by MFC, at a sensitivity level of 10-4.
Time-to-progression (TTP) was measured from the
moment of MRD assessment to the date of progression or
last visit. Curves were plotted by the Kaplan-Meier
method, and the log rank test was used to estimate the sta-
tistical significance of differences observed between curves.
The Cox proportional hazards model was used to estimate
hazard ratios (HR) and 95% confidence intervals (95%CI),
as well as to perform a multivariate analysis including
patients’ MRD status (dichotomized into negative/posi-
tive), type of treatment (dichotomized into yes/no):
autoSCT, novel agents; proteasome inhibition, immune
modulators, as well as the event of extramedullary relapses
(dichotomized into yes/no). The X2 test was used to esti-
mate the statistical significance of differences observed
between groups. For all statistical analyses, the SPSS soft-
ware (v.15.0; SPSS Inc., Chicago, IL, USA) was used.
First, we focused on the more standard treatment popu-
lation of the 31 patients achieving CR after salvage therapy
in the non-alloSCT setting (Table 1). Among them, 13
achieved MRD-negative status (42%) whereas in the
remaining 18 (58%) cases persistent MRD was detected by
MFC (median 0.2% clonal PC among total BM leukocytes;
range 0.01-1.67%). MRD-negative cases showed a median
TTP of 75 months, whereas 17 of the 18 MRD-positive CR
patients progressed with a median TTP of only 14 months
(HR: 2.8; 95%CI: 1.0-7.6; P=0.039) (Figure 1A). Similar
results were observed while specifically analyzing patients’
TTP during the first three years after MRD assessment
(Figure 1B), with median TTP for MRD-negative cases not
yet reached versus 14 months among MRD-positive
patients (P=0.037). On the multivariate analysis for TTP
that included, in addition to patients’ MRD status, the type
of treatment being used (i.e. autoSCT, novel agents; protea-
some inhibition, immune modulators) and the event of
extramedullary relapses, MRD status showed an HR of
2.96 (95%CI: 0.8-10.7) and a P value equal to 0.098; all
other variables were non-significant and showed inferior 
P values (data not shown). Additional studies in larger series
of patients are, therefore, warranted to assess the inde-
pendent prognostic value of MRD monitoring over the
type of salvage therapy and type of relapse in MM (i.e.
medullary vs. extramedullary). Afterwards, we focused on
the 21 patients in CR after alloSCT, and observed that 10
(48%) failed to eradicate MRD (median of 0.12% clonal PC
among total BM leukocytes; range 0.01-0.7%).
Surprisingly, there were no significant differences according
to the presence versus absence of MRD in TTP (P=0.77)
among patients in CR after alloSCT. These observations led
us to investigate whether this phenomenon could be asso-
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Table 1. Minimal residual disease rates and prognostic value accord-
ing to the different treatment schemas used on relapsing multiple
myeloma patients.
Treatment                                          MRD positive        MRD negative
                                                          n=28; (54%)          n=24; (46%)
Chemotherapy without SCT, n=20             14 (70%)                    6 (30%)
Conventional, n=6                                              4                                  2
Novel agents, n=14                                           10                                 4
Chemotherapy with autoSCT, n=11            4 (47%)                     7 (63%)
Chemotherapy with alloSCT, n=21            10 (48%)                   11 (52%)
MRD: minimal residual disease; SCT: stem cell transplantation.
ciated with a higher incidence of extramedullary relapses
(and therefore potentially missed on BM monitoring) after
alloSCT. Accordingly, a total of 11 extramedullary relapses
were observed among patients in CR after alloSCT, 7 of
which among MRD-negative patients. By contrast, only 2
of 31 patients in the non-alloSCT setting had
extramedullary relapses (both MRD-positive). 
In summary, we show that CR patients after salvage
therapy constitute a heterogeneous subgroup with approx-
imately half of the cases showing persistent MRD and early
relapse (approx. one year). Patients with MRD-negativity
experience significantly prolonged TTP outside of the
alloSCT setting, and further studies with larger series of
patients are warranted to confirm if MRD-negativity could
become an end point for novel drugs being tested in
relapsed/refractory patients. The likelihood of
extramedullary relapses even among MRD-negative
patients after alloSCT suggests that, at least for this partic-
ular therapeutic strategy, response assessment should
include combined medullar and extramedullary (PET/CT)
measure of MRD. 
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Figure 1. (A) Time-to-progression (TTP) of multiple myeloma (MM)
patients in complete response (CR) after salvage chemotherapy
with or without autoSCT (n=31), according to the absence [mini-
mal residual disease (MRD)-negative] versus presence of pheno-
typically aberrant clonal plasma cells (MRD-positive). (B) Specific
analysis of TTP during the first three years after MRD assessment
among MM patients in CR after salvage chemotherapy with or
without autoSCT. (C) TTP of MM patients in CR after salvage
chemotherapy with alloSCT (n=21), according to patients’ MRD
status.
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